NCT04577833 - A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer | Biotech Hunter

Enrollment

136

Participants

Timeline

Start Date

November 13, 2020

Primary Completion Date

October 15, 2021

Study Completion Date

December 31, 2026

Conditions

Prostatic Neoplasms

Interventions

DRUG

Niraparib

Niraparib will be administered orally.

DRUG

Abiraterone Acetate (AA)

Abiraterone Acetate will be administered orally.

DRUG

Prednisone

Prednisone will be administered orally.

Trial Locations (16)

2610

GZA Ziekenhuizen- Campus St Augustinus, Wilrijk

9000

Universitair Ziekenhuis Gent, Ghent

28040

Hosp Univ Fund Jimenez Diaz, Madrid

28050

Hosp Univ Hm Sanchinarro, Madrid

29010

Hosp Virgen de La Victoria, Málaga

33000

Institut Bergonié, Centre de Lutte Contre le Cancer, Bordeaux

84119

START Mountain Region, West Valley City

94163

HIA Begin, Saint-Mandé

0112

Arensia Exploratory Medicine, Tbilisi

Md2025

Arensia Exploratory Medicine, Chisinau

3015 GD

Erasmus MC, Rotterdam

80 214

Uniwersyteckie Centrum Kliniczne, Gdansk

02-781

Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy, Warsaw

171 76

Karolinska Universitetssjukhuset Solna, Stockholm

01135

ARENSIA Exploratory Medicine Unit, Kyiv

NE7 7DN

Sir Bobby Robson Unit, Northern Centre for Cancer Care, Newcastle upon Tyne

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY